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an autocrine TnFα–Tumor necrosis 
Factor receptor 2 loop Promotes 
epigenetic effects inducing human 
Treg stability In Vitro
Paulo C. M. Urbano1, Hans J. P. M. Koenen1, Irma Joosten1 and Xuehui He1,2*
1 Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center,  
Nijmegen, Netherlands, 2 College of Computer Science, Qinghai Normal University, Xining, China
A crucial issue for Treg-based immunotherapy is to maintain a bona fide Treg phenotype 
as well as suppressive function during and after ex vivo expansion. Several strategies have 
been applied to harness Treg lineage stability. For instance, CD28 superagonist stimulation 
in  vitro, in the absence of CD3 ligation, is more efficient in promoting Treg proliferation, 
and prevention of pro-inflammatory cytokine expression, such as IL-17, as compared to 
CD3/CD28-stimulated Treg. Addition of the mTOR inhibitor rapamycin to Treg cultures 
enhances FOXP3 expression and Treg stability, but does impair proliferative capacity. A 
tumor necrosis factor receptor 2 (TNFR2) agonist antibody was recently shown to favor 
homogenous expansion of Treg in vitro. Combined stimulation with rapamycin and TNFR2 
agonist antibody enhanced hypo-methylation of the FOXP3 gene, and thus promoting 
Treg stability. To further explore the underlying mechanisms of rapamycin and TNFR2 
agonist-mediated Treg stability, we here stimulated FACS-sorted human Treg with a CD28 
superagonist, in the presence of rapamycin and a TNFR2 agonist. Phenotypic analysis of 
expanded Treg revealed an autocrine loop of TNFα–TNFR2 underlying the maintenance of 
Treg stability in vitro. Addition of rapamycin to CD28 superagonist-stimulated Treg led to a 
high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation 
with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound 
TNFα. Moreover, our data showed that the expression of histone methyltransferase EZH2, 
a crucial epigenetic modulator for potent Treg suppressor function, was enhanced upon 
stimulation with CD28 superagonist. Interestingly, rapamycin seemed to downregulate 
CD28 superagonist-induced EZH2 expression, which could be rescued by the additional 
addition of TNFR2 agonist antibody. This process appeared TNFα-dependent manner, since 
depletion of TNFα using Etanercept inhibited EZH2 expression. To summarize, we propose 
that an autocrine TNFα–TNFR2 loop plays an important role in endorsing Treg stability.
Keywords: regulatory T cells, tumor necrosis factor receptor 2, TnFα, rapamycin, tumor necrosis factor receptor 
2 agonist antibody, Treg stability
inTrODUcTiOn
CD4+FOXP3+ regulatory T cells (Treg) inhibit autoreactive effector T cells (Teff) and are important 
for immune homeostasis. The absence of Treg leads to lethal autoimmune disease in mice and 
humans, thereby highlighting their critical role in preventing autoimmunity (1). Notwithstanding 
the first successes of translation of Treg-based cell therapy into the clinic, a critical concern in 
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utilizing Treg is their stability. Treg lineage stability is defined by 
a stable expression of the transcription factor FOXP3, a highly 
demethylated Treg-specific demethylation region (TSDR), potent 
suppressive capacity and lack of pro-inflammatory cytokine pro-
duction (2, 3). For the efficacy of Treg-based immunotherapy, the 
development of optimal ex vivo expansion protocols that yield 
high numbers of stable Treg is a prerequisite. Standard expansion 
protocols using anti-CD3/anti-CD28 mAb-coated microbeads 
plus exogenous rhIL-2 not only lead to high cell yields (4, 5) but 
also reveal Treg plasticity, whereby Treg loose FOXP3 and start 
producing IL-17A and IFNγ (6–8). Stimulating Treg with an anti-
CD28 superagonist antibody (CD28-SA) results in efficient Treg 
expansion and reduced pro-inflammatory cytokine production 
in vitro (9). Since Treg are less susceptible to rapamycin-mediated 
inhibition of cell proliferation as compared to non-Treg cells, 
this mTOR inhibitor is often added to Treg expansion cultures 
to increase the purity of the final cell product (10–16). However, 
rapamycin does limit Treg growth both in  vitro and in  vivo  
(17, 18). It is of interest to note that the combined addition of a 
tumor necrosis factor receptor 2 (TNFR2) agonistic monoclonal 
antibody and rapamycin not only rescues rapamycin-mediated 
inhibition of Treg proliferation but also leads to a highly homog-
enous Treg phenotype as well as a stable suppressive function 
upon expansion (19, 20).
TNFα is initially expressed on cell surface as a membrane-
bound TNFα (mTNFα), which can be cleaved by a metal-
loprotease TNF-alpha converting enzyme (TACE) to generate 
soluble TNFα (sTNFα) (21). Both sTNFα and mTNFα bind to 
TNFR2, but only mTNFα is capable to fully activate TNFR2 
downstream signal events including NFkB pathway, which 
is involved in cytokine storm, cell survival and proliferation 
(22, 23). TNFR2 is constitutively expressed on both murine 
and human Treg, and TNFR2+ Treg are the most suppressive 
Treg subpopulation (24–27). The TNFα–TNFR2 interaction 
is required for Treg mediated suppression in a mouse model 
of autoimmune-mediated colitis (28, 29). Several studies 
demonstrated that sTNFα preserved or even increased FOXP3 
expression, as well as Treg suppressive capacity in both mice 
and humans (19, 25, 30, 31). But anti-TNF therapy of patients 
with active rheumatoid arthritis restored FOXP3 expression 
as well as suppressive function (32). Notably, the high serum 
levels of TNFα were associated with increased peripheral Treg 
numbers in patients with colorectal cancer and hepatocellular 
carcinoma, where blockade of TNFα/TNFR2 signals inhibited 
Treg cell expansion and benefited cancer therapy (33), thereby 
indicating that TNFα is capable of mediating Treg expansion.
Treg lineage stability is ultimately maintained by sustained 
expression of FOXP3 and Treg-specific epigenetic modification 
patterns (34). In response to inflammatory cues, FOXP3 recruits 
the histone methyltransferase EZH2 at the FOXP3-bound loci 
and selectively deposits the transcriptional suppression mark 
trimethylation of histone H3 at lysine 27 (H3K27me3) (35). In 
mice, it was shown that EZH2 expression was induced in a CD28-
dependent manner and the mutant mice bearing Treg-specifically 
depletion of EZH2 developed fetal multi-organ autoimmunity 
with excessive T  cell activation (36). Of note, EZH2-deficient 
FOXP3+ murine T  cells secreted pro-inflammatory cytokines 
(37). It is not yet clear whether human Treg show similar EZH2 
expression metrics. Microarray analysis of human naïve T cells 
revealed that EZH2 gene was the most highly induced CD28-
dependent chromatin modifier (36).
Having previously established that a CD28 superagonist 
mAb (CD28-SA) acts as a very effective stimulus to support 
efficient Treg expansion (9), and that the combined use of 
rapamycin and TNFR2 agonist enhanced the demethylation of 
TSDR, thus harnessing Treg stability (20), we further explored 
Treg ex vivo stimulation and maintenance of stability by 
combining CD28 superagonist mAb, rapamycin and TNFR2 
agonist mAb. We found that the harnessing effect of rapamycin 
and TNFR2 agonist on Treg stability was achieved through 
an autocrine loop of TNFα via TNFR2, whereby rapamycin 
enhanced TNFR2 expression and TNFR2 agonist increased the 
production of TNFα. Moreover, our data demonstrated that, 
similar to murine Treg, the histone methyltransferase EZH2 was 
induced in human Treg upon CD28 superagonist stimulation. 
Intriguingly, the combined addition of rapamycin and TNFR2 
agonist maintained EZH2 expression in a TNFα-dependent 
manner.
MaTerial anD MeThODs
isolation of human Treg
Peripheral blood mononuclear cells were isolated by density gra-
dient centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, 
Norway) of buffy coats that were purchased from Sanquin blood 
bank (Region South-East, Netherlands). All donors gave written 
informed consent for the use of these buffy coats for scientific 
research purposes, and according to Dutch law. CD4+ T cells were 
enriched using the RosetteSep™ human CD4+ T cell enrichment 
cocktail and processed according to manufacturer’s recommen-
dations (StemCell Technologies, Vancouver, BC, Canada). This 
typically resulted in a >95% purified CD4+ T cell population in 
the absence of CD8+ cells. To obtain high purity Treg, subsequent 
FACS sorting of CD4+CD25high Treg was performed using a BD 
FACSAria cell sorter (BD Biosciences, Erembodegem, Belgium) 
after labeling CD4+ cells with CD25/Pe-Cy7 (M-A251; BD 
Biosciences).
Treg cell culture
FACS-sorted CD4+CD25high Treg were cultured for 7 days with 
IL-2 (200  U/mL) containing medium alone as non-stimulated 
control, or together with different combinations of CD28 super-
agonist (CD28-SA, 1 µg/mL, Clone ANC28.1/5D10, Cat# 177-
820, preservative free; Ancell, Bayport, MN, USA), rapamycin 
(Rap, 1 µM, Sigma-Aldrich, St. Louis, MO, USA), and TNFR2 
agonist mAb (2.5 µg/mL, Clone MR2-1, Hycult, Netherlands). 
Exogenous recombinant human (rh) TNFα (50  ng/mL, R&D, 
Minneapolis, MN, USA) was used to replace TNFR2 agonist 
where indicated. Etanercept (10  µg/mL, ETN-Enbrel®, Pfizer) 
was added to cell culture for the depletion of TNFα. Cells were 
harvested at day 7 of culture for phenotypic analysis, and cul-
ture supernatants were collected and stored for the subsequent 
cytokine analysis.
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Flow cytometry and antibodies
Cells were phenotypically analyzed using a multicolor flow 
cytometer Navios (Beckman Coulter, Mijdrecht, Netherlands). 
The following conjugated mAb were used: CD25/Pe-Cy7 
(M-A251), HLA-DR/FITC (L243) (both from BD Bioscience); 
TIGIT/PE (MBSA43, eBioscience, Vienna, Austria), CD3/ECD 
(UCHT1), CD4/PE-Cy5.5 (1388.2), CD8/APC-AF700 (B9.11) 
(all from Beckman Coulter), TNFR2/APC (#22235; R&D), 
and Fixable Viability Dye eFluor780 (eBioscience). To detect 
the expression of mTNFα, cells were first stained with biotin-
labelled Infliximab followed with APC-conjugated streptavidin 
(eBioscience). For intracellular staining, EZH2/PE (11/EZH2, 
BD Bioscience), FOXP3/eFluor 450 (PCH101), and Helios/
AlexFluor 647 (22F6) (both from eBioscience) were used after 
fix-perm-treatment of cells, according to the manufacturer’s 
instructions. Isotype matched control antibodies were used to 
define marker settings. Data were analyzed using the software 
Kaluza (Beckman Coulter).
cytokine Detection assay
IL-17A, IFNγ, and TNFα were determined in the culture super-
natants using Luminex cytokine assays (Invitrogen), according 
to the manufacturer’s instructions. The lower levels of detectable 
cytokines were IL-17A (2 pg/mL), IFNγ (2.3 pg/mL), and TNFα 
(2.3 pg/mL).
coculture suppression assays
FACS-sorted Treg cells were cultured under the stimulation 
conditions described above. Thereafter, cultured Treg were col-
lected at day 7 of culture, washed, and added at different ratios to 
CFSE-labeled CD4+CD25− responder T cells (Tresp). Coculture 
mixture was stimulated with anti-CD3/anti-CD28 mAb-coated 
microbeads at a bead-to-cell ratio of 1:5 for 3 days before analyz-
ing the dilution of CFSE using flow cytometry.
Quantitative real-time Pcr (rT-qPcr)
Total RNA was extracted by using the RNeasy Plus Micro kit 
(Qiagen, Hilden, Germany) followed by cDNA synthesis using the 
SuperScript III First-Strand Synthesis System and Oligo(dT)20 
primers (Thermo Fisher Scientific, Waltham, MA, USA). Taqman 
gene expression assays were purchased from Thermo Fisher 
Scientific (see Table S1 in Supplementary Material). RT-qPCR 
cycle values (CT) obtained for specific mRNA expression in each 
sample were normalized to the CT values of the housekeeping 
gene HPRT1 (endogenous control). The relative mRNA expres-
sion of gene interested was calculated using 2−ΔCT formula.
statistics
Statistical analysis was performed using the GraphPad Prism 
software version 5.0 (GraphPad Software Inc., San Diego, 
CA, USA). Statistical differences were calculated using the 
Wilcoxon matched pairs signed rank test, or the non-parametric 
Friedman test or Kruskal–Wallis test plus Dunn’s post hoc test 
for multiple comparisons, where applicable. Differences were 
considered statistically significant at *p < 0.05, **p < 0.01, or 
***p < 0.001.
resUlTs
rapamycin increases the expression  
of TnFr2 on cD28 superagonist-
stimulated Treg
Tumor necrosis factor receptor 2 is known to be crucial for phe-
notypic and functional stability of Treg, especially in an inflam-
matory environment (29). We thus started off by examining the 
expression level of TNFR2 on human FACS-sorted CD4+CD25high 
Treg stimulated with a CD28 superagonist mAb (CD28-SA) in the 
presence or absence of Rap and/or TNFR2 agonist. Treg cultured 
in IL-2 containing medium alone were used as non-stimulated 
control, and the expression of TNFR2 was determined by flow 
cytometry at day 7 of culture. In the absence of CD28-SA stimula-
tion, TNFR2 agonist itself neither revealed a potential cytotoxic 
effect on cultured Treg nor the regulation of TNFR2 expression 
as compared to Treg cultured under the medium control condi-
tion (Figure S1A–B in Supplementary Material). Stimulation of 
Treg using CD28-SA significantly enhanced the expression of 
TNFR2 (92.5 ± 2.9 vs. 70.5 ± 3.1% for medium control, p < 0.05), 
while the addition of Rap to CD28-SA stimulated Treg resulted 
in the highest expression level of TNFR2, both in frequency 
(95.5 ±  1.7%; p <  0.01) and in median fluorescence intensity 
[median fluorescent intensity (MFI), 18.9 ±  3.9 vs. 2.1 ±  0.2 
for medium control; p <  0.001] (Figure  1A). The addition of 
TNFR2 agonist to CD28-SA stimulated Treg hardly affected 
TNFR2 expression as compared to CD28-SA (MFI, 6.10 ± 1.2 vs. 
7.93 ± 1.1, p > 0.05). Surprisingly, Treg cultured with the triple 
combination of CD28-SA + Rap + TNFR2 agonist expressed a 
similar level of TNFR2 (77.9 ± 6.3%) as that observed for control 
Treg (70.5 ±  3.1%, p >  0.05) (Figure  1A). The potential cyto-
toxic effect of TNFR2 agonist on cultured Treg is unlikely as we 
observed similar cell viability under all conditions tested (Figure 
S2 in Supplementary Material). Interference of the TNFR2 ago-
nist with the subsequent detection of TNFR2 in this case was also 
not likely, as we selectively chose an APC-conjugated anti-TNFR2 
mAb (Clone #22235) derived from a different clone than the 
TNFR2 agonist (Clone MR2-1). FITC-conjugated TNFR2 mAb 
derived from the same clone MR2-1 as TNFR2 agonist used in 
Treg culture failed to detect any expression of TNFR2, whereas 
APC-conjugated TNFR2 did (Figure S3 in Supplementary 
Material). Instead, we propose that binding of TNFR2 agonist 
might have caused the internalization of the TNFR2–ligand 
complex (38), leading to lower levels of detection. The rapamycin 
enhanced TNFR2 expression was also reflected at mRNA level 
since the highest TNFRSF1B (TNFR2) mRNA was observed 
under the condition of CD28-SA  +  Rap (Figure  1B). Taken 
together, the data suggest that Rap increases TNFR2 expression 
on Treg following cell stimulation.
The addition of rap and TnFr2 agonist  
to cD28 superagonist-stimulated Treg 
initiates an autocrine TnFα–TnFr2 loop
Loss of Treg stability implies that Treg acquire the capacity to 
produce effector cytokines upon stimulation. We therefore 
measured the amount of IL-17A, IFNγ, and TNFα in the culture 
FigUre 1 | Rapamycin increases TNFR2 expression on human Treg following the stimulation with CD28 superagonist. Flow cytometry of TNFR2 expression on 
human Treg that were expanded for 7 days under the indicated conditions (legends): non-stimulated medium control (Medium), stimulation with CD28 superagonist 
mAb (CD28-SA) with and without rapamycin in the absence or presence of TNFR2 agonist mAb (CD28-SA, CD28-SA + TNFR2-ago, CD28-SA + Rap,  
CD28-SA + Rap + TNFR2-ago). (a) Dot plots show TNFR2 vs. FOXP3 expression of one representative donor. Cumulative data showing the percentage as well as 
the median fluorescent intensity (MFI) of TNFR2 expression on Treg cultured under the conditions as indicated on the X-axis. N = 5. Lines show the mean values. 
(B) Relative mRNA expression of TNFRSF1B in Treg stimulated with the conditions as described on the X-axis. N = 4. All data are shown as mean ± SEM. Friedman 
with Dunn’s post hoc test was used for statistical analysis. Asterisks indicate significant differences (*p < 0.05, **p < 0.01, or ***p < 0.001).
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supernatants of Treg that were stimulated under distinct condi-
tions. Neither Treg cultured in medium control condition nor 
that cultured in the presence of TNFR2 agonist produced any 
cytokines (Figure S1C in Supplementary Material), whereas upon 
CD28-SA stimulation, Treg started to produce low, but detect-
able amounts of IL-17A, IFNγ, and TNFα. The addition of Rap 
to the culture prevented CD28-SA stimulated Treg to produce 
IL-17A (0.1 ± 0.1 vs. 16.2 pg/mL ± 6.7, p < 0.05), as well as TNFα 
(9.7 ± 3.9 vs. 28.6 pg/mL ± 9.1, p < 0.01), but it marginally affected 
IFNγ production (Figure  2A). The addition of TNFR2 agonist 
to the culture minimally regulated CD28-SA induced IL-17A 
and IFNγ production, whereas it increased the amount of TNFα 
FigUre 2 | Addition of rapamycin and TNFR2 agonist to CD28-superagonist stimulated Treg initiates an autocrine TNFα–TNFR2 loop. FACS-sorted human Treg 
were stimulated for 7 days as indicated on the X-axis; the culture supernatants were collected at day 7 and the presence of cytokines were determined using 
Luminex. (a) Cumulative data showing the amount of IL-17A, IFNγ, and TNFα produced by Treg cultured as described on the X-axis. N = 8. (B) Flow cytometry 
analysis of membrane-bound TNFα (mTNFα) as well as FOXP3 expression at day 7 of culture. Dot plots showing one representative donor. Graph shows the 
cumulative data. N = 4. Percentage of mTNFα-positive cells is indicated in the dot plots. (c) Relative mRNA expression of TNFA in Treg stimulated with the 
conditions as described on the X-axis. N = 4. (D) FACS-sorted human Treg were stimulated with CD28-SA + Rap or CD28-SA + Rap + TNFR2 agonist in the 
presence or absence of the TNFα-blocking agent Etanercept (ETN). Cumulative data showing the percentage of mTNFα+ cells at day 7 of culture. N = 3. All data are 
shown as mean ± SEM. Friedman with Dunn’s post hoc test were used for statistical analysis. Asterisks indicate significant differences (*p < 0.05, **p < 0.01).
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(139.0 ± 32.85 vs. 28.62 pg/mL ± 9.1, p < 0.05). Notably, adding 
TNFR2 agonist to Rap treated CD28-SA stimulated Treg resulted 
in a similar high amount of TNFα (103.7 pg/mL ± 16.4) as that 
of Treg stimulated with CD28-SA + TNFR2 agonist (Figure 2A).
Soluble TNFα is derived from its precursor mTNFα, whereby 
mTNFα is cleaved by the TNFα-converting enzyme TACE to 
release its extracellular C-terminal portion (21). To test whether the 
enhanced soluble TNFα production was due to the increased con-
version from its precursor, we analyzed the expression of mTNFα 
on Treg cultured under different combinations of CD28-SA, Rap, 
and TNFR2 agonist. At day 7 of culture, few mTNFα+ cells were 
detected on CD28-SA stimulated Treg (1.5 ±  0.5%), whereas 
addition of Rap enhanced mTNFα expression (16.4 ±  5.9%). 
However, triple stimulation with CD28-SA  +  Rap  +  TNFR2 
agonist further promoted the frequency of mTNFα+ cells 
(40.0  ±  3.3%, p  <  0.05, Figure  2B). Similarly, the highest 
expression of TNFRA (TNFα) mRNA was observed under triple 
stimulation with CD28-SA + Rap + TNFR2 agonist (Figure 2C). 
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This data indicates that the combined addition of Rap and TNFR2 
agonist to CD28-SA stimulated Treg did increase their capacity to 
produce more TNFα. So, Rap treatment increased the expression 
of TNFR2 on CD28-SA stimulated Treg cells, while the additional 
treatment with a TNFR2 agonist significantly enhanced TNFα 
production. This might well result in an autocrine loop of TNFα 
via TNFR2, thus leading to stabilization of the Treg phenotype.
To find further support for this autocrine TNFα–TNFR2 loop, 
we depleted TNFα by using Etanercept. As shown in Figure 2D, 
regardless of the stimulation condition used, extra addition of 
Etanercept resulted in decreased mTNFα expression, albeit not 
statistically significant. Taken together, the data show that there 
is a positive feedback loop in the regulation of TNFα cytokine 
production upon TNFα–TNFR2 interaction.
The TnFα–TnFr2 interaction is required 
for a homogenous Treg Phenotype
Potent Treg function is associated with high expression of 
specific cell markers, including Treg lineage transcription factor 
FOXP3, Helios, and the co-inhibitory receptor TIGIT (39–41). 
We thus performed phenotypic analysis of Treg that were cul-
tured for 7 days under distinct stimulatory conditions. TNFR2 
agonist itself hardly influenced the Treg phenotype (Figure 
S1D in Supplementary Material). When cells were stimulated 
with CD28-SA, the addition of Rap preserved or even slightly 
increased the expression of CD25 as well as FOXP3, Helios, and 
TIGIT (Figure 3A). Intriguingly, the addition of TNFR2 agonist 
to CD28-SA stimulated Treg clearly enhanced the expression of 
HLA-DR (81.5 ± 5.9 vs. 44.8 ± 3.9%, p < 0.01) while it hardly 
regulated other markers tested (Figure  3A). The combined 
addition of Rap and TNFR2 agonist to CD28-SA stimulated 
Treg significantly enhanced the frequency of the HLA-DR, 
TIGIT and Helios positive fractions (Figure 3A, p < 0.01), and 
preserved the high expression of FOXP3. Of note, when exog-
enous soluble rhTNFα was used instead of the TNFR2 agonist, 
we observed a similar expression of CD25, FOXP3, TIGIT, and 
Helios, but not of HLA-DR, which was only enhanced by the 
presence of the TNFR2 agonist (Figure  3A). Treg stimulated 
with CD28-SA + Rap + TNFR2 agonist were highly suppressive, 
as determined in in vitro suppression assays. We did not observe 
significant suppressive advantages as compared to the Treg that 
were cultured under the other stimulatory culture conditions 
(Figure  3B). Interestingly, depletion of TNFα under triple 
stimulation with CD28-SA + Rap + TNFR2 agonist significantly 
downregulated the expression of HLA-DR, TIGIT, Helios, and 
FOXP3 (Figure  3C). These data further support the notion 
of an autocrine TNFα–TNFR2 feedback loop that promotes a 
homogeneous Treg population upon activation, whereby Rap 
enhances TNFR2 expression and TNFR2 agonist stimulation 
increases TNFα production.
The addition of rap and TnFr2 agonist to 
cD28 superagonist-stimulated Treg leads 
to activation of nFκB signal Pathway
To test the potential involved downstream signal pathways that 
were induced by triple stimulation with CD28-SA + Rap + TNFR2 
agonist, we focused on NFκB pathway target genes using RT-qPCR 
analysis. Treg stimulated with CD28-SA or CD28-SA  +  Rap 
were also included. As shown in Figure 4, the addition of Rap 
to CD28-SA stimulated Treg led to the enhanced RELA (RelA) 
mRNA expression, whereas the combined addition of Rap and 
TNFR2 agonist significantly increased the NFκB pathway gene 
expression including NFKB1 (NFκB1/p65), NFKB2 (NFκB2/
p50), NFKBIA (IkBα), and RELB (RelB). The data suggest that 
the activation of the NFκB pathway underlies the enhanced Treg 
stability mediated by the autocrine TNFα–TNFR2 loop.
TnFα–TnFr2 signaling  
regulates the expression of  
histone Methyltransferase eZh2
Recently, CD28-dependent induction of histone methyltras-
ferase EZH2 was reported in murine Treg (36). In the same 
study, EZH2 was shown to be crucial for Treg lineage stability 
following cell activation. Here, we first performed a time kinetic 
analysis of EZH2 expression in human Treg stimulated with 
CD28 superagonist. From day 2 of culture, enhanced EZH2 
expression was detected, and the highest frequency of EZH2-
positive Treg was observed at day 7 (47.6 ± 5.5 vs. 2.9 ± 1.3% for 
medium control, p < 0.001) (Figure 5A). Thereafter, we focused 
on day 7 to analyze the effect of Rap and/or TNFR2 agonist on 
the expression of EZH2. As shown in Figure 5B, TNFR2 agonist 
itself slightly enhanced the expression of EZH2 (13.4 ± 2.8 vs. 
2.9 ± 1.0% for medium control group, p = 0.1250). When Treg 
were stimulated with CD28-SA, addition of TNFR2 agonist to 
the culture minimally affected EZH2 expression (51.6 ± 10.3 vs. 
51.0 ± 6.6% for CD28-SA condition), whereas addition of Rap 
decreased EZH2 expression (32.3 ± 5.9%) when compared to 
CD28-SA condition (p < 0.05). Of note, the combined addition 
of Rap and TNFR2 agonist resulted in a similar frequency of 
EZH2-positive cells (53.6 ±  6.3%) as compared to CD28-SA 
condition, suggesting that the presence of TNFR2 agonist could 
rescue Rap-mediated downregulation of EZH2. Thus, TNFR2 
agonist induced signals were positively involved in the regulation 
of EZH2 expression. Indeed, when TNFα was depleted by add-
ing Etanercept to triple stimulated (CD28-SA + Rap + TNFR2 
agonist) Treg, the frequency of EZH2-positive cells was signifi-
cantly decreased (Figure 5C). Altogether, the data indicate that 
EZH2 expression is modulated by TNFα–TNFR2-mediated 
pathways.
DiscUssiOn
The limited number of circulating Treg and the instability and 
plasticity of Treg function are main issues that hamper successful 
application of Treg for clinical cell-based immunotherapy. In the 
past decades, several interventions have been used to optimize 
Treg ex vivo expansion protocols that not only maximize Treg 
proliferation but also maintain their potent suppressive func-
tion. Standard Treg expansion protocols include anti-CD3 and 
anti-CD28 mAb together with the exogenous addition of rhIL-2 
cytokines (4). In the absence of anti-CD3, single stimulation 
of human Treg with a CD28 superagonist induces polyclonal 
FigUre 3 | Continued
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FigUre 4 | Addition of rapamycin and TNFR2 agonist to CD28-superagonist stimulated Treg cultures results in the activation of the NFκB pathway. FACS-sorted 
Treg cells were stimulated using CD28-SA, CD28-SA + Rap, or CD28-SA + Rap + TNFR2 agonist for 4 days. The mRNA expression of NFκB family of members 
was analyzed using RT-qPCR. All data are shown as mean ± SEM. N = 4. Friedman with Dunn’s post hoc test was used for statistical analysis. Asterisks indicate 
significant differences (*p < 0.05).
FigUre 3 | Addition of rapamycin and TNFR2 agonist to CD28-superagonist stimulated Treg cultures leads to a homogenous Treg phenotype that is dependent on 
the interaction of TNFα–TNFR2. (a) Flow cytometry of CD25, HLA-DR, TIGIT, FOXP3, and Helios expression on CD28-SA stimulated Treg that were additionally 
cultured with Rapamycin (Rap) with or without TNFR2 agonist or soluble rhTNFα as indicated. Dot plots show representative result of one blood donor. Cumulative 
data are given in the graphs. N = 8–11. Lines show the mean values. (B) Treg cultured under the indicated conditions (legend) were harvested at day 7 of culture, 
washed, allowed to recuperate, and analyzed for their suppressive capacity in a CFSE-based coculture suppression assay. N = 4. Friedman with Dunn’s post hoc 
test were used for statistical analysis. (c) FACS-sorted human Treg were stimulated with CD28-SA + Rap + TNFR2 agonist in the presence or absence of the 
TNFα-blocking agent Etanercept (ETN). Dot plots showing TIGIT vs. HLA-DR, and Helios vs. FOXP3 expression of one representative experiment. Cumulative data 
are shown in the graph. N = 7. Numbers in dot plots show the percentage of positive cells. All data are shown as mean ± SEM. Friedman with Dunn’s post hoc test 
was used for statistical analysis. Asterisks indicate significant differences (*p < 0.05, **p < 0.01, or ***p < 0.001).
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expansion of Treg with enhanced Treg stability (9). The mTOR 
inhibitor rapamycin enhances FOXP3 expression, preserves Treg 
stability, and increases Treg suppressor capacity in vitro as well 
as in  vivo, but rapamycin also inhibited Treg cell proliferation 
(15, 17, 42, 43). Previously, we showed that the combined 
addition of rapamycin and TNFR2 agonist to Treg cell culture 
facilitates ex vivo expansion of Treg (20). In this study, we found 
that rapamycin enhanced the expression of TNFR2 on activated 
Treg and that the additional supplementation of a TNFR2 
agonist enhanced the production of TNFα. This resulted in a 
positive autocrine feedback loop of TNFα–TNFR2 signaling 
that promotes Treg stability as indicated by the high expres-
sion of FOXP3, Helios, and EZH2, and the low production of 
the pro-inflammatory cytokine IL-17A. Despite this increased 
expression of FOXP3, Helios, and EZH2, we did not observe an 
increase in suppressor potential. This is remarkable, since our 
group and others have demonstrated before that TNFα–TNFR2 
stimulation increases Treg function in both humans and mice 
(19, 20, 44). Previously, we reported that Treg stimulated with 
CD3/CD28-microbeads +  Rap +  TNFR2 agonist hardly pro-
duced IL-17A and IFNγ, and these cells revealed superior sup-
pressive activity at a Treg:Tresp ratio of 1:8 as compared to CD3/
CD28 or CD3/CD28 + Rap-stimulated Treg (20). In our current 
study, CD28-SA + Rap + TNFR2 agonist-treated Treg showed 
similar suppressive capacity as Treg treated with CD28SA, 
CD28SA +  Rap, or CD28SA +  TNFR2 agonist. It seems that 
TNFR2-mediated signals somehow interact with T cell receptor/
CD3 induced downstream targets and promote Treg suppressor 
function. Furthermore, Treg display their immunosuppressive 
function via controlling T  cell proliferation and cytokine pro-
duction, as well as regulating the stimulatory capacity of antigen 
presenting cells. Especially, inhibition of T cell effector function 
can occur independently of suppression of proliferation (45, 
46). Loss of Treg lineage commitment is often reflected by the 
decreased expression of Treg markers on their progenies, which 
mostly occurs following several rounds of stimulation.
Tumor necrosis factor receptor 2 plays a crucial role in Treg 
cell biology. Both human and murine Treg constitutively express 
high levels of TNFR2 as opposed to non-Treg cells. The interac-
tion of TNFα–TNFR2 promoted both Treg proliferation and 
their suppressor capacity (25, 47). Stimulation of TNFR2 using 
a TNFR2 agonist antibody resulted in a homogenous expansion 
of human Treg (19, 20). Interestingly, we here demonstrate that 
rapamycin enhanced the expression of TNFR2 on activated 
human Treg, whereas it inhibited TNFα cytokine production. 
When TNFR2 agonist was added to rapamycin-treated Treg cell 
cultures, we found the preferential stimulation of Treg with high 
expression levels of HLA-DR, FOXP3, Helios, and TIGIT, as well 
FigUre 5 | CD28 superagonist induces EZH2 expression in human Treg and addition of rapamycin downregulates EZH2 frequency which can be rescued by 
TNFR2 agonist in a TNFα-dependent manner. Flow cytometry of EZH2 expression in FACS-sorted human Treg that were cultured for 7 days in medium (Medium) or 
stimulated with CD28 superagonist mAb (CD28-SA) with or without Rapamycin (Rap) in the absence or presence of TNFR2 agonist mAb, or the TNFα blocker 
Etanercept (ETN). (a) Representative experiment showing EZH2 expression at different days in time (indicated at the top). Graph shows cumulative data. N = 3. 
Open circle: medium control; shaded circle, CD28-SA stimulation. (B) Representative overlay histograms showing EZH2 expression at day 7 of the culture. Graph 
shows cumulative data. N = 12. Numbers in the overlay histograms show the percentage of EZH2-positive cells. Gray line: isotype control; black line, Treg 
expanded under conditions where described at the top. N = 4 for the medium control and TNFR2 agonist conditions, N = 8 for CD28-SA + TNFR2 agonist 
condition, and N = 12 for other conditions. Kruskal–Wallis with Dunn’s post hoc test was used for statistical analysis. (c) Representative overlay histogram showing 
EZH2 expression in Treg that were stimulated with CD28-SA + Rap + TNFR2 agonist together with or without ETN. N = 7. Graph shows the cumulative data. 
Wilcoxon matched pairs signed rank test was used for statistical analysis. All data are shown as mean ± SEM. Asterisks indicate significant differences (*p < 0.05, 
**p < 0.01, or ***p < 0.001).
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as a high TNFα-producing potential. That depletion of TNFα 
using Etanercept led to a reduction of Treg-associated markers 
including FOXP3, Helios, TIGIT, and EZH2 further supports 
a role for TNFα–TNFR2 signaling in the FOXP3 expression of 
Treg and the notion of an autocrine TNFα–TNFR2 feedback loop 
that promotes Treg stability. Consistent with our data, in an acute 
graft-versus-host disease (aGvHD) mouse model the treatment 
with a selective TNFR2 agonist led to the in vivo expansion of 
host Treg and the protection from aGvHD (48). Interestingly, the 
suppressive activity of Treg to control GvHD seems to depend 
on TNFα produced by donor T cells and TNFR2 expressed on 
Treg in allogeneic hematopoietic stem cell transplantation (49). 
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In response to TCR stimulation, CD4+FOXP3− Teff as well 
as cytotoxic CD8+ cells also upregulates TNFR2 expression. 
TNFR2-positive CD4 Teff are highly proliferative and more 
resistant to Treg-mediated inhibition (50). Intriguingly, TNFR2 
agonism effectively and selectively induces the apoptosis of 
insulin-autoreactive CD8+ cells in patients with type 1 diabetes 
(51). Therefore, specific TNFR2 agonism would have two desired 
cellular immune effects for treatment of autoimmune diseases: 
(1) selective death of autoreactive T cells and (2) expansion of 
beneficial Treg. The positive effect of TNF–TNFR2 activation on 
Treg numbers is also reported in cancer patients. For example, 
enhanced abundance of TNFR2+ Treg and high TNFα serum level 
were reported in patients with ovarian cancer, lung cancer as well 
as colorectal cancer (33, 52, 53). In a mouse model of colorectal 
cancer, blockade of TNFα–TNFR2 signaling prevented rapid 
resurgence of Treg after cyclophosphamide-induced lymphode-
pletion and inhibited the growth of established tumors (33).
The effect of TNFα on human Treg is not yet fully clear. 
Oppenheim and colleagues showed TNF-induced Treg (iTreg) 
proliferation and survival via TNFR2 (25, 47) and TNFR2+ Treg 
exhibited maximal suppressive capacity (29). In the context of 
autoimmunity, Treg suppressive function is optimized by patho-
genic T cells and TNFα is one of factors involved in this opti-
mization (54). Zaragoza et al. reported that TNFα together with 
IL-2 increased the expression CD25 and FOXP3 and maintained 
the suppressive activity of human Treg (31). In our cell culture 
system, we noticed that, upon stimulation with CD28-SA + Rap, 
the addition of exogenous soluble rhTNFα showed a similar effect 
as the addition of TNFR2 agonist on the maintenance of a bona 
fide Treg phenotype, whereas blocking TNFα signaling using 
Etanercept decreased the frequency of FOXP3-positive cells 
(Figure 3C). This supports the positive effect of TNFα on the Treg 
phenotype. Previously, TNFα was shown to downregulate Treg 
function since the TNFα-blocking agent Infliximab increased 
FOXP3 expression and restored their suppressive function in 
rheumatoid arthritis (RA) patients (32). However, a follow-up 
study demonstrated that iTreg, but not naturally occurring 
Treg (nTreg) were increased in RA patients following anti-TNF 
therapy (55). Of note, nTreg and iTreg differentially require 
TNFα signals for optimal suppressive function, at least in mice 
(28). Nie et  al. showed that TNFα impaired Treg suppressive 
function via the dephosphorylation of FOXP3 protein (30). They 
also demonstrated that rhTNFα did not affect FOXP3 expression; 
instead, TNFα enhanced the expression of protein phosphatase 
PP1 which mediated FOXP3 dephosphorylation, thus rending 
the Treg defective. It is worth noting that anti-TNF therapy often 
results in psoriatic and lupus-like symptoms in patients being 
treated for other conditions (56); this suggests a direct correlation 
between TNF and immune suppression.
Metabolic changes directly modify T cell function. Signaling 
via PI3K–Akt–mTOR pathway facilitates the induction of glucose 
transporter Glut 1 and aerobic glycolysis in Teff (57). Interestingly, 
proliferative Treg cells have high mTOR activity as well as high 
glucose uptake together with downregulated FOXP3 expression 
and impaired suppressive capacity (58). FOXP3 expression is 
inversely related to Akt activity (59) and promotes mitochondrial 
oxidative metabolism. It would seem that Treg proliferation and 
suppressive function is regulated by separate metabolic path-
ways. Rapamycin induced retardation of Treg growth might be 
caused by the shifting of glycolysis metabolism to lipid oxidative 
metabolism via the inhibition of the PI3K–Akt–mTOR pathway 
and enhanced FOXP3 expression. Non-canonical NFκB activa-
tion upon TNFα stimulation is involved in T  cell survival and 
differentiation (23). Here, we showed that the combined addition 
of rapamycin and TNFR2 agonist resulted in high expression of 
Treg associated marker, and activation of NFκB pathway. The 
autocrine feedback loop of TNFα and TNFR2 might fine-tune the 
metabolic balance between glycolysis and oxidative phosphoryla-
tion, thereby favoring homogenous Treg proliferation together 
with the preservation of potent suppressive function. Further 
experiments on metabolic pathway regulation are required to 
test this hypothesis.
Epigenetic mechanisms that alter chromatin organization 
are important to control the differentiation and maintenance 
of polarized T  cell subsets. EZH2 functions primarily within 
the polycomb repressive complex 2 and catalyzes the tri-
methylation of lysine 27 on the exposed N-terminal tail of 
histone H3 (H3K27me3), a histone modification associated 
with repression of expression of nearby genes. EZH2, via the 
formation of a complex with FOXP3 in activated Treg, is crucial 
for proper Treg suppressive function since mutant mice bearing 
Treg-specific deletion of EZH2 developed fatal inflammation 
associated with massive T cell activation and cytokine produc-
tion (35, 36). Mice that specifically lack EZH2 expression in Treg 
develop spontaneous inflammatory bowel disease (37), which 
further supports the crucial role of EZH2 for Treg function. 
Recently, human Treg were reported to express EZH2 mRNA 
(60). In our current study, we demonstrate that CD28 super-
agonist stimulation induced EZH2 expression in human Treg, 
which was decreased by the presence of rapamycin, whereas the 
combined addition of rapamycin and TNFR2 agonist to Treg 
cultures maintained expression of EZH2 in a TNFα-dependent 
manner. Interestingly, the NFkB family of proteins RelA as well 
as c-Rel were reported to enhance luciferase activity in an EZH2 
reporter system, and c-Rel regulated the induction of EZH2 
gene expression in activated primary murine lymphocytes and 
human leukemia cell lines (61).
In summary, we showed that stimulation of human Treg 
using a triple combination of CD28 superagonist, rapamycin, 
and TNFR2 agonist leads to homogenous expansion of Treg that 
reveal a stable and suppressive phenotype. Mechanistically, rapa-
mycin enhanced TNFR2 expression of the CD28 superagonist-
stimulated Treg; the TNFR2 agonist promotes TNFα production 
and this supports an autocrine TNFα–TNFR2 feedback loop that 
favors high expression of TIGIT, FOXP3, Helios, and EZH2.
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